[EN] AMINOARYL SUBSTITUTED FIVE-MEMBERED RING HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES<br/>[FR] COMPOSES HETEROCYCLIQUES A NOYAU A CINQ ELEMENTS A SUBSTITUTION AMINOARYLE POUR LE TRAITEMENT DE MALADIES
申请人:AB SCIENCE
公开号:WO2006064375A9
公开(公告)日:2006-08-03
[EN] The present invention relates to novel compounds selected from aminoaryl five-membered ring heterocycles that selectively modulate, regulate and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. [FR] La présente invention concerne de nouveaux composés choisis parmi des hétérocycles à noyau à cinq éléments aminoaryle modulant, régulant et/ou inhibant sélectivement la transduction de signal médiée par certaines tyrosine kinases natives et/ou mutantes impliquées dans une pluralité de maladies humaines et animales, telles que les maladies prolifératives, métaboliques, allergiques et dégénératives.
Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides – A SAR study on the bioisosterism of pyrimidine and imidazole
A series of N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides were synthesized and tested for inhibition of PDGFR and FLT3 autophosphorylation. The novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides, obtained by replacement of the pyrimidine system in Imatinib (1) with an imidazole ring, exhibit potent inhibitory activity on PDGFR, similar to the parent compound (IC(50) (9e)=0